+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Throat Cancer Therapeutics Market 2019-2023 - Product Image

Global Throat Cancer Therapeutics Market 2019-2023

  • ID: 4787714
  • Report
  • May 2019
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Sanofi
  • MORE
Global Throat Cancer Therapeutics Market: About this market

Throat cancer is a type of head and neck cancer that affects the tissues in the pharynx or the larynx. The throat cancer treatment market analysis considers the treatment of pharyngeal cancer and laryngeal cancer. Our analysis also considers the treatment of throat cancer in Asia, Europe, North America, and South America. In 2018, the pharyngeal cancer segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as changing lifestyle will play a significant role in the pharyngeal cancer segment to maintain its market position. Also, our global throat cancer therapeutics market looks at factors such as increasing incidence of throat cancer, increasing the use of tobacco products, and increasing risk factors. However, the preference for alternative treatment options, severe adverse effects, and high treatment cost may hamper the growth of the throat cancer therapeutics industry over the forecast period.

Global Throat Cancer Therapeutics Market: Overview

Increasing incidence of throat cancer

The global throat cancer treatment market has witnessed an increase in the number of throat cancer cases despite advancements in the R&D of therapeutics. The condition is increasingly becoming prevalent in countries across Europe, Asia, and North America. In the US, the mortality rate for the condition increased from 2.5 deaths per every 100,000 people to 2.6 deaths per every 100,000 people over the past decade. The increasing prevalence of throat cancer has increased the number of awareness campaigns to aid in the early diagnosis of the condition. The increasing incidence of throat cancer is one of the major factors driving the growth of the global throat cancer therapeutics market at a CAGR of nearly 7% over the forecast period.

Strong pipeline

The increasing prevalence of throat cancer has encouraged many large and mid-sized vendors to conduct R&Ds to develop novel drugs for the condition. Many vendors in the market have developed novel therapies that are in the late stages of clinical trials for the treatment of various head and neck cancer indications, including pharyngeal and laryngeal cancer. These developments among vendors are expected to fuel the growth of the global throat cancer therapeutics market size.

Competitive Landscape

With the presence of a few players, the global throat cancer therapeutics market is fairly concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several throat cancer therapeutics companies, that include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Sanofi.

Also, the throat cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Pharyngeal cancer - Market size and forecast 2018-2023
  • Laryngeal cancer - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 16: EXPLORE

List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global throat cancer therapeutics market pipeline: Overview
Exhibit 18: Global throat cancer therapeutics market pipeline: Snapshot
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Pharyngeal cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Pharyngeal cancer - Year-over-year growth 2019-2023 (%)
Exhibit 23: Laryngeal cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Laryngeal cancer - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 50: Bristol-Myers Squibb Co. - Business segments
Exhibit 51: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 52: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 53: Bristol-Myers Squibb Co. - Key offerings
Exhibit 54: Bristol-Myers Squibb Co. - Key customers
Exhibit 55: Eli Lilly and Co. - Vendor overview
Exhibit 56: Eli Lilly and Co. - Business segments
Exhibit 57: Eli Lilly and Co. - Organizational developments
Exhibit 58: Eli Lilly and Co. - Geographic focus
Exhibit 59: Eli Lilly and Co. - Segment focus
Exhibit 60: Eli Lilly and Co. - Key offerings
Exhibit 61: Eli Lilly and Co. - Key customers
Exhibit 62: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 63: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 68: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 69: Merck & Co. Inc. - Vendor overview
Exhibit 70: Merck & Co. Inc. - Business segments
Exhibit 71: Merck & Co. Inc. - Organizational developments
Exhibit 72: Merck & Co. Inc. - Geographic focus
Exhibit 73: Merck & Co. Inc. - Segment focus
Exhibit 74: Merck & Co. Inc. - Key offerings
Exhibit 75: Merck & Co. Inc. - Key customers
Exhibit 76: Sanofi - Vendor overview
Exhibit 77: Sanofi - Business segments
Exhibit 78: Sanofi - Organizational developments
Exhibit 79: Sanofi - Geographic focus
Exhibit 80: Sanofi - Segment focus
Exhibit 81: Sanofi - Key offerings
Exhibit 82: Sanofi - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors
    Note: Product cover images may vary from those shown
    3 of 4

    Loading
    LOADING...

    4 of 4

    FEATURED COMPANIES

    • Bristol-Myers Squibb Co.
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Sanofi
    • MORE
    The following companies are recognised as the key players in the global throat cancer treatment market: Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Sanofi.

    Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strong pipeline.”

    According to the report, one of the major drivers for this market is the increasing incidence of throat cancer.

    Further, the report states that one of the major factors hindering the growth of this market is the preference for alternative treatment options.

    The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
    Note: Product cover images may vary from those shown
    5 of 4
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Sanofi
    Note: Product cover images may vary from those shown
    Adroll
    adroll